Comparative effectiveness and safety of direct-acting oral anticoagulants (DOACS) for the reduction of recurrent venous thromboembolism in cancer patients: A protocol for systematic review and network meta-analysis using a generalized pairwise modeling methodology.
Adult
Aged
Comparative Effectiveness Research
Factor Xa Inhibitors
/ therapeutic use
Female
Humans
Male
Middle Aged
Models, Statistical
Neoplasms
/ complications
Network Meta-Analysis
Recurrence
Research Design
Secondary Prevention
/ methods
Systematic Reviews as Topic
Treatment Outcome
Venous Thromboembolism
/ drug therapy
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
Apr 2020
Apr 2020
Historique:
entrez:
4
4
2020
pubmed:
4
4
2020
medline:
9
4
2020
Statut:
ppublish
Résumé
There has been a significant improvement in both our understanding and therapeutic choices available to clinicians for the management of cancer associated thrombosis (CAT). Even with the recent publication of a systematic review and landmark trials demonstrating the non-inferiority of DOACS-based anticoagulation strategy compared to the standard of care in patients with CAT, there is unresolved uncertainty regarding the exact hierarchy of risks and effectiveness of various DOAC analogues in these cohorts of patients. We will carry out a network meta-analyses, utilizing a novel generalized pairwise methodology to generate direct and indirect comparisons between the various DOAC analogues. We will search the following databases for studies that satisfies pre-specified inclusions criteria; these include PubMed, EMBASE, Cochrane library, Clinicaltrials.gov, conference abstracts among other sources. The primary efficacy and safety outcomes are recurrent VTE and major hemorrhagic events, respectively. Two reviewers will Search the databases independently with the view to identify studies that meet eligibility criteria. The methodological quality of the included studies will be determined using a recently validated risk of bias assessment tool. We expect that the result of this review will ascertain the hierarchy of risks and effectiveness of various DOAC analogues in patients with CAT. Results of this review will assist in informed decisions making regarding therapeutic guidelines of DOAC in CAT.
Sections du résumé
BACKGROUND
BACKGROUND
There has been a significant improvement in both our understanding and therapeutic choices available to clinicians for the management of cancer associated thrombosis (CAT). Even with the recent publication of a systematic review and landmark trials demonstrating the non-inferiority of DOACS-based anticoagulation strategy compared to the standard of care in patients with CAT, there is unresolved uncertainty regarding the exact hierarchy of risks and effectiveness of various DOAC analogues in these cohorts of patients.
METHOD
METHODS
We will carry out a network meta-analyses, utilizing a novel generalized pairwise methodology to generate direct and indirect comparisons between the various DOAC analogues. We will search the following databases for studies that satisfies pre-specified inclusions criteria; these include PubMed, EMBASE, Cochrane library, Clinicaltrials.gov, conference abstracts among other sources. The primary efficacy and safety outcomes are recurrent VTE and major hemorrhagic events, respectively. Two reviewers will Search the databases independently with the view to identify studies that meet eligibility criteria. The methodological quality of the included studies will be determined using a recently validated risk of bias assessment tool.
RESULTS
RESULTS
We expect that the result of this review will ascertain the hierarchy of risks and effectiveness of various DOAC analogues in patients with CAT.
CONCLUSION
CONCLUSIONS
Results of this review will assist in informed decisions making regarding therapeutic guidelines of DOAC in CAT.
Identifiants
pubmed: 32243404
doi: 10.1097/MD.0000000000019679
pii: 00005792-202004030-00049
pmc: PMC7440321
doi:
Substances chimiques
Factor Xa Inhibitors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e19679Références
Int J Evid Based Healthc. 2019 Jun;17(2):106-120
pubmed: 31094882
PLoS Med. 2009 Jul 21;6(7):e1000100
pubmed: 19621070
N Engl J Med. 2018 Feb 15;378(7):615-624
pubmed: 29231094
Thromb Haemost. 2018 Sep;118(9):1668-1678
pubmed: 30103252
Int Heart J. 2018 Jan 27;59(1):126-135
pubmed: 29279522
BMJ. 2011 Oct 18;343:d5928
pubmed: 22008217
Adv Exp Med Biol. 2017;906:123-135
pubmed: 27620308
Thromb Res. 2019 Jan;173:158-163
pubmed: 29506866
Thromb Res. 2017 Feb;150:86-89
pubmed: 28064037
JAMA. 2015 Aug 18;314(7):677-686
pubmed: 26284719
Int J Evid Based Healthc. 2018 Dec;16(4):187-194
pubmed: 29621039
Front Pharmacol. 2019 Jul 10;10:773
pubmed: 31354488
Thromb Haemost. 2015 Jul;114(1):150-7
pubmed: 25739680
Blood. 2013 Sep 5;122(10):1712-23
pubmed: 23908465
Curr Oncol. 2018 Oct;25(5):329-337
pubmed: 30464682